Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 10, 2021

–(BUSINESS WIRE)– CURE Pharmaceutical Holding Corp. We’ve been working to develop safe, accurately-dosed cannabis solutions for several years now and we believe that this collaboration will help us take that initiative to the next level and expand our reach,” said Rob Davidson, CURE Pharmaceutical CEO. OXNARD, Calif.–(BUSINESS

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

Cannabis Law Report

OCTOBER 29, 2021

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin. Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use. October 27, 2021. DENVER, Oct.

Pharmaceutical 52

Pharmaceutical Research and Development Data Safety 52

Veriheal

AUGUST 12, 2021

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

Cannabis Law Report

JANUARY 18, 2022

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Safety 52

Safety Chronic Pain Research and Development Pharmaceutical 52

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. The Phase 2 TSC trial, the CALM trial, was an open-label trial to evaluate the safety and tolerability of adjunctive ganaxolone treatment in patients with seizures associated with TSC. About Marinus Pharmaceuticals. 484-253-6792.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. BRC is a specialty pharmaceutical company that holds several DEA Registrations and is pioneering the federally legal cannabis space in the USA.

DEA 59

DEA Pharmaceutical Research and Development Compliance 59

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Ganaxolone was generally well-tolerated and no new safety findings emerged in the LGS subgroup. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

NORML

MAY 26, 2020

A team of Israeli researchers conducted a randomized placebo-controlled clinical trial to assess the safety and efficacy of a novel, metered-dose cannabis inhaler in 27 patients with chronic pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”

Clinical Trials 248

Clinical Trials Chronic Pain Cannabinoids Patients 248

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Project CBD

JULY 28, 2023

with unknown pharmacological and safety profiles.” These hemp hustlers are in it for the money, making active pharmaceutical ingredients using process chemistry and producing formulated end-products like vape pens, gummies, and sodas in garages, airplane hangars, basements, and warehouses. Dr. Mark A.

THC 212

THC Cannabinoids Hemp Research and Development 212

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Project CBD

AUGUST 23, 2023

Earlier this year, the Food & Drug Administration disclosed that it would not regulate non-pharmaceutical CBD products, thereby putting the onus on Congress to devise an appropriate regulatory framework for cannabidiol and other hemp-derived cannabinoids. Caffeine can also be found in pharmaceutical 33 and non-pharmaceutical products.)

Cannabinoids 141

Cannabinoids Hemp THC Safety 141

Project CBD

NOVEMBER 11, 2023

In general, I think that botanical medicine is safer than pharmaceutical medicine, that the chances of causing harm are much less. So just on safety alone, it’s worth using it. I include pharmaceutical drugs in that category. In general, I think that botanical medicine is safer than pharmaceutical medicine.

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

Cannabis Law Report

JULY 14, 2021

Patients are looking to their medical providers for information on cannabis safety, potential for interactions with pharmaceuticals, and therapeutic applications. cannabis industry is failing to provide consumers and medical patients with much-needed guidance on appropriate use and crucial guarantees of product safety.

Policy 105

Policy Medicine Research and Development Safety 105

Cannabis Law Report

JULY 26, 2021

SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110. SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled, cross-over study. About SciSparc (OTCQB: SPRCY): SciSparc Ltd.

Research and Development 105

Research and Development Supply Chain Pharmaceutical Treatment 105

Cannabis Law Report

JANUARY 11, 2023

PRESS RELEASE UK company Chanelle McCoy Health granted Ethics Approval to commence Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance CMH-CBD-001 using their Ultra Pure Synthetic Cannabinoid (CBD) formulation with pharmaceutical grade FDA registered raw material.

Clinical Trials 52

Clinical Trials CBD Sleep Pharmaceutical 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Chronicles

APRIL 2, 2019

The Food and Drug Administration says the May 31 meeting will discuss the science, safety and sale of cannabis compounds like CBD. The FDA has approved a pharmaceutical version of CBD to treat rare seizure disorders. It also said any products that make drug or treatment claims also need to be approved by the FDA.

CBD 113

CBD Food Pharmaceutical Collective 113

Cannabis Law Report

AUGUST 12, 2021

Since 2013, medicinal cannabis has been legalized in the Czech Republic due to the amendment to the Act on pharmaceuticals, otherwise known as Act No. With medical research indicating that using the plant provides significant medical benefits, the Czech Chamber of Deputies suggested a revision to the government’s Act on pharmaceuticals.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., Dr. Wakshlag is currently available for interviews to discuss the results of the safety study as well as his clinical trials.

Safety 45

Safety CBD Clinical Trials Oil 45

TheAnswerPage

MARCH 20, 2023

A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis. A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams.”

Epilepsy 52

Epilepsy Topical Safety Treatment 52

Cannabis Law Report

SEPTEMBER 10, 2021

1 producer of pharmaceutical-grade cannabis nutrients since 1999, creating an intuitive line of products trusted by growers all over the world. The company is committed to the health and safety of all of our teammates in compliance with the most up to date state and federal regulations._*. JUNIOR COUNSEL. West Hollywood, CA.

Compliance 98

Compliance Compliance Safety Policy 98

PrestoDoctor

DECEMBER 12, 2023

Comparison of cannabis and pharmaceutical drugs for common senior health conditions When it comes to treating common health conditions in seniors, cannabis often proves to be a viable alternative to pharmaceutical drugs. Many pharmaceutical drugs come with side effects and the risk of dependency.

Medicine 98

Medicine Chronic Pain Consumption Pharmaceutical 98

Cannabis Law Report

AUGUST 27, 2021

The Edmonton, Alberta-based cannabis giant also said that its subsidiary and Ethypharm were selected by the National Agency for the Safety of Medicines and Health Products to supply the entire medical cannabis dried flower range sourced from the company’s EU GMP facility in Denmark Aurora Nordic to French patients as part of the program.

Patients 105

Patients Programs Pharmaceutical Compliance 105

Canna Law Blog

FEBRUARY 25, 2022

If you keep a pulse on this issue, you know that for the past three years, the FDA has held the position that CBD cannot be marketed as a dietary ingredient because it was first studied and approved as a drug ingredient in GW Pharmaceuticals’ Epidiolex ( Drug Exclusion Rule ). According to NPA’s petition, the U.S.

CBD 80

CBD Safety Data Food 80

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JUNE 17, 2021

Patients are looking to their medical providers for information on cannabis safety, potential for interactions with pharmaceuticals, and therapeutic applications. cannabis industry is failing to provide consumers and medical patients with much-needed guidance on appropriate use and crucial guarantees of product safety.

Policy 80

Policy Research and Development Medicine Safety 80

Cannabis Law Report

AUGUST 5, 2021

Additionally, the technology backed by the patent will be essential for transforming variable psychedelic raw materials into pharmaceutical-grade standardized extracts. This approval represents important progress in the development of our intellectual property,” Benjamin Lightburn, CEO of Filament, said in a press release. “At

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

TheAnswerPage

JUNE 12, 2022

A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis. A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams.”

Epilepsy 52

Epilepsy Topical Safety Treatment 52

MMJ Recs

JUNE 26, 2020

Marijuana Use In Safety Sensitive Job Duties In Oklahoma. Safety Sensitive jobs and work duties were detailed. Employers were given the legal right to take MMJ use into account when their employees would be engaged in Safety Sensitive work. What Are Safety Sensitive Jobs In Oklahoma MMJ Law? Dispensing pharmaceuticals.

Marijuana 69

Marijuana Safety Pharmaceutical Patients 69

Cannabis Law Report

DECEMBER 2, 2021

Products that are listed as having been verified as meeting the minimum quality standards are unapproved medicines – there has been no assessment of their safety or efficacy. MW Pharma Limited t/a NUBU Pharmaceuticals. CDC Pharmaceuticals Ltd. CDC Pharmaceuticals Ltd. CDC Pharmaceuticals Ltd. Date Verified.

Medicine 52

Medicine Pharmaceutical Sativa THC 52

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. Over time, Maryland has refined its approach to ensure the accessibility and safety of MMJ for its residents.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98